STOCK TITAN
  1. Home
  2. Sec-filings
  3. REVB
  4. [Form 4] REVELATION BIOSCIENCES, INC. Insider Trading Activity

Revelation Biosciences (REVB) CFO reports tax-withholding share sale via trust

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Revelation Biosciences Chief Financial Officer reports a routine tax-related share sale through a trust. On the reported date, 13,285 shares of common stock were disposed of at a weighted average price of $1.10 per share to satisfy required tax withholding on vested restricted stock awards. The filing states this transaction was mandatory and that the CFO did not exercise investment discretion. After this tax-withholding disposition, an indirect trust holding stands at 92,063 shares of common stock, and an affiliated LLC holds 2 additional common shares indirectly.

Positive

  • None.

Negative

  • None.
Insider Zygmont Chester Stanley III
Role Chief Financial Officer
Type Security Shares Price Value
Tax Withholding Common Stock 13,285 $1.10 $15K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 92,063 shares (Indirect, by Trust)
Footnotes (1)
  1. Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.09 to $1.13, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee. Shares are held by Czeslaw Capital Fund, LLC. Chester S Zygmont III is the sole manager of Czeslaw Capital Fund, LLC.
Tax-withholding shares disposed 13,285 shares Common stock sold to satisfy tax obligations on vesting
Weighted average sale price $1.10 per share Tax-withholding disposition of common stock
Post-transaction trust holdings 92,063 shares Common stock indirectly held by The Zygmont Family Trust
Additional LLC holdings 2 shares Common stock indirectly held by Czeslaw Capital Fund, LLC
Sale price range $1.09–$1.13 per share Price range for multiple transactions in tax-withholding sale
tax withholding obligations financial
"solely to satisfy required tax withholding obligations arising upon the vesting"
restricted stock awards financial
"tax withholding obligations arising upon the vesting of restricted stock awards"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirect ownership financial
"Shares are held by The Zygmont Family Trust Dated October 25, 2016"
tax-withholding disposition financial
"transaction_action: tax-withholding disposition"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zygmont Chester Stanley III
(Last)(First)(Middle)
C/O REVELATION BIOSCIENCES, INC.
4660 LA JOLLA VILLAGE DR., SUITE 100
(Street)
SAN DIEGO CALIFORNIA 92122
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/30/2026F13,285(1)D$1.1(2)92,063Iby Trust(3)
Common Stock2ILLC(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.09 to $1.13, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.
4. Shares are held by Czeslaw Capital Fund, LLC. Chester S Zygmont III is the sole manager of Czeslaw Capital Fund, LLC.
/s/ J.P. Galda, as attorney-in-fact for Chester S Zygmont III05/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Revelation Biosciences (REVB) report for its CFO?

Revelation Biosciences reported an indirect tax-related share disposition for its CFO. 13,285 common shares were sold by the issuer solely to cover tax withholding obligations from vested restricted stock awards, making it a mandatory, non-discretionary transaction rather than an open-market trade.

How many Revelation Biosciences (REVB) shares were sold for tax withholding?

A total of 13,285 Revelation Biosciences common shares were sold to satisfy tax withholding obligations. The filing notes these shares were sold on the reporting person’s behalf by the issuer in multiple transactions at prices between $1.09 and $1.13 per share, with a weighted average of $1.10.

At what price were the Revelation Biosciences (REVB) tax-withholding shares sold?

The weighted average sale price was $1.10 per Revelation Biosciences share. According to the filing, the actual transactions occurred in a range between $1.09 and $1.13 per share, and detailed per-trade pricing information is available from the company or the reporting person on request.

How many Revelation Biosciences (REVB) shares does the CFO indirectly hold after this Form 4?

Following the tax-withholding disposition, the CFO’s trust indirectly holds 92,063 Revelation Biosciences common shares. The filing shows this balance after the 13,285-share sale for tax obligations, and it is reported as an indirect ownership position through The Zygmont Family Trust dated October 25, 2016.

Through which entities are the Revelation Biosciences (REVB) shares held for the CFO?

The filing shows indirect holdings via two entities. Most shares are held by The Zygmont Family Trust dated October 25, 2016, where Chester S. Zygmont III is a trustee. An additional 2 common shares are held by Czeslaw Capital Fund, LLC, managed solely by Chester S. Zygmont III.

Was the Revelation Biosciences (REVB) CFO’s share sale a discretionary open-market transaction?

The filing states the sale was not discretionary. Shares were sold by the issuer solely to meet required tax withholding obligations from restricted stock vesting, and the CFO did not exercise investment discretion over the sale, distinguishing it from a voluntary open-market trade decision.